Artykuły w czasopismach na temat „TP53 polymorphism”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „TP53 polymorphism”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Dabre, Soayebo, Abdou Azaque Zoure, Touwendpoulimdé Isabelle Kiendrébéogo, et al. "Involvement of p.R72P and PIN3 Ins16bp (TP53) Polymorphisms and the I157T (CHEK2) Mutation in Breast Cancer Occurrence in Burkina Faso." Asian Pacific Journal of Cancer Biology 8, no. 2 (2023): 135–45. http://dx.doi.org/10.31557/apjcb.2023.8.2.135-145.
Pełny tekst źródłaNishizuka, Satoshi, Yukimi Ohmori, Takeshi Iwaya, and Keisuke Koeda. "Recurrence risk evaluation in stage IB gastric cancer with TP53 codon 72 polymorphism." Journal of Clinical Oncology 37, no. 15_suppl (2019): 4044. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4044.
Pełny tekst źródłaDiakite, Brehima, Yaya Kassogue, Mamoudou Maiga, et al. "Abstract 7326: TP53 p.Pro47Ser polymorphism in breast cancer susceptibility in Mali." Cancer Research 84, no. 6_Supplement (2024): 7326. http://dx.doi.org/10.1158/1538-7445.am2024-7326.
Pełny tekst źródłaLiao, Fan, Li Yuan, Jinhong Zhu, Wei Chen, Yemu Zhao, and Jing He. "Association of TP53 rs1042522 C>G Polymorphism with Glioma Risk in Chinese Children." BioMed Research International 2022 (August 13, 2022): 1–6. http://dx.doi.org/10.1155/2022/2712808.
Pełny tekst źródłaMoe, Svein Erik, Fredrik A. Erland, Siren Fromreide, et al. "The TP53 Codon 72 Arginine Polymorphism Is Found with Increased TP53 Somatic Mutations in HPV(−) and in an Increased Percentage among HPV(+) Norwegian HNSCC Patients." Biomedicines 11, no. 7 (2023): 1838. http://dx.doi.org/10.3390/biomedicines11071838.
Pełny tekst źródłaDeben, Christophe, Jolien Van den Bossche, Nele Van Der Steen, et al. "Deep sequencing of the TP53 gene reveals a potential risk allele for non–small cell lung cancer and supports the negative prognostic value of TP53 variants." Tumor Biology 39, no. 2 (2017): 101042831769432. http://dx.doi.org/10.1177/1010428317694327.
Pełny tekst źródłaIordanishvili, Saba, Tornike Metreveli, Elene Lipartia, et al. "The HPV-TP53-MALAT1 Axis: Unravelling interactions in cervical cancer development." PLOS ONE 18, no. 10 (2023): e0291725. http://dx.doi.org/10.1371/journal.pone.0291725.
Pełny tekst źródłaUsategui-Martín, Ricardo, Nadia Galindo-Cabello, Salvador Pastor-Idoate, et al. "A Missense Variant in TP53 Could Be a Genetic Biomarker Associated with Bone Tissue Alterations." International Journal of Molecular Sciences 25, no. 3 (2024): 1395. http://dx.doi.org/10.3390/ijms25031395.
Pełny tekst źródłaF. Fahmy, Nahed, Nagwa S. Ahmed, Ghada Galal, et al. "Study the Role of Tp53 in the Development of Hepatocellular Carcinoma in HCV Infected Patients." Egyptian Journal of Medical Microbiology EJMM29, no. 4 (2020): 165–72. http://dx.doi.org/10.51429/ejmm29421.
Pełny tekst źródłaMaiga, Mamoudou, Brehima Diakite, Yaya Kassogue, et al. "Abstract 7328: Relationship between PIN3 16bp duplication of TP53 and HPV in HIV women in Mali." Cancer Research 84, no. 6_Supplement (2024): 7328. http://dx.doi.org/10.1158/1538-7445.am2024-7328.
Pełny tekst źródłaHeinze, Britta, Leonie J. M. Herrmann, Martin Fassnacht, et al. "Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma." European Journal of Endocrinology 170, no. 5 (2014): 707–17. http://dx.doi.org/10.1530/eje-13-0788.
Pełny tekst źródłaCintra, Hellen Silva, Juliana Castro Dourado Pinezi, Graziella Dias Pinheiro Machado, et al. "Investigation of Genetic Polymorphisms Related to the Outcome of Radiotherapy for Prostate Cancer Patients." Disease Markers 35 (2013): 701–10. http://dx.doi.org/10.1155/2013/762685.
Pełny tekst źródłaTanara, G., C. Falugi, A. Cesario, S. Margaritora, P. Russo, and A. Cosimi. "TP53 Codon 72 Polymorphism does not Affect Risk of Cervical Cancer in Patients from the Gambia." International Journal of Biological Markers 18, no. 4 (2003): 280–83. http://dx.doi.org/10.1177/172460080301800405.
Pełny tekst źródłaGrigor’eva, I. N., O. V. Efimova, A. A. Gurazheva, and V. N. Maksimov. "Frequency of hyperglycemia and polymorphism of TNF and TP53 genes in patients with acute pancreatitis, chronic pancreatitis, pancreatic cancer." Diabetes mellitus 24, no. 6 (2021): 511–20. http://dx.doi.org/10.14341/dm12439.
Pełny tekst źródłaCavic, Milena, Jelena Spasic, Ana Krivokuca, et al. "TP53 and DNA-repair gene polymorphisms genotyping as a low-cost lung adenocarcinoma screening tool." Journal of Clinical Pathology 72, no. 1 (2018): 75–80. http://dx.doi.org/10.1136/jclinpath-2018-205553.
Pełny tekst źródłaRodrigues, Guilherme Oliveira, Larissa Sousa Silva Bonasser, Maurício De Lima Santos, Caroline Ferreira Fratelli, Caliandra Maria de Souza Silva, and Izabel Cristina Rodrigues da Silva. "TP53 Arg72Pro polymorphism and its relationship with major depressive disorder." Concilium 24, no. 14 (2024): 214–23. http://dx.doi.org/10.53660/clm-3726-23p17.
Pełny tekst źródłaZmorzynski, Szymon Andrzej, Iwona Korszen-Pilecka, Magdalena Wojcierowska-Litwin, et al. "TP53 polymorphism in plasma cell myeloma." Folia Histochemica et Cytobiologica 55, no. 4 (2018): 203–11. http://dx.doi.org/10.5603/fhc.a2017.0022.
Pełny tekst źródłaVerheijen, F. M., M. Sprong, J. M. E. Kloosterman, G. Blaauw, J. H. H. Thijssen, and M. A. Blankenstein. "TP53 Mutations in Human Meningiomas." International Journal of Biological Markers 17, no. 1 (2002): 42–48. http://dx.doi.org/10.1177/172460080201700105.
Pełny tekst źródłaGao, Lin-Bo, Li-Juan Li, Xin-Min Pan, et al. "A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer." Biological Chemistry 394, no. 3 (2013): 415–20. http://dx.doi.org/10.1515/hsz-2012-0297.
Pełny tekst źródłaOlkova, MV, VS Petrushenko, and GYu Ponomarev. "Analysis of 13 TP53 and WRAP53 polymorphism frequencies in russian populations." Features of HIV and SARS-CoV-2 coinfection in a pandemic, no. 2021(1) (January 2021): 30–39. http://dx.doi.org/10.24075/brsmu.2021.001.
Pełny tekst źródłaSłomiński, Bartosz, Maria Skrzypkowska, Monika Ryba-Stanisławowska, Małgorzata Myśliwiec, and Piotr Trzonkowski. "Associations of TP53 codon 72 polymorphism with complications and comorbidities in patients with type 1 diabetes." Journal of Molecular Medicine 99, no. 5 (2021): 675–83. http://dx.doi.org/10.1007/s00109-020-02035-1.
Pełny tekst źródłaTsuchiya, Yasuo, Sergio Baez, Alfonso Calvo, et al. "Evidence that Genetic Variants of Metabolic Detoxication and Cell Cycle Control Are Not Related to Gallbladder Cancer Risk in Chilean Women." International Journal of Biological Markers 25, no. 2 (2010): 75–78. http://dx.doi.org/10.1177/172460081002500203.
Pełny tekst źródłaZhao, Yichao, Chaoqian Zhu, Qing Chang, et al. "TP53 rs28934571 polymorphism increases the prognostic risk in hepatocellular carcinoma." Biomarkers in Medicine 15, no. 9 (2021): 615–22. http://dx.doi.org/10.2217/bmm-2020-0418.
Pełny tekst źródłaBarlow, Jason W., Marieke Mous, Joe C. Wiley, et al. "Germ Line BAX Alterations Are Infrequent in Li-Fraumeni Syndrome." Cancer Epidemiology, Biomarkers & Prevention 13, no. 8 (2004): 1403–6. http://dx.doi.org/10.1158/1055-9965.1403.13.8.
Pełny tekst źródłaDrokow, Emmanuel Kwateng, Yuqing Chen, Hafiz Abdul Waqas Ahmed, et al. "The relationship between leukemia and TP53 gene codon Arg72Pro polymorphism: analysis in a multi-ethnic population." Future Oncology 16, no. 14 (2020): 923–37. http://dx.doi.org/10.2217/fon-2019-0792.
Pełny tekst źródłaF. A. Nerweyi, Farida. "The Relationship of Gliomas with Tp53 Rs1042522 C > G And Gliomas in Duhok." Journal Of Duhok University 23, no. 2 (2020): 157–65. http://dx.doi.org/10.26682/sjuod.2020.23.2.17.
Pełny tekst źródłaF. A. Nerweyi, Farida. "The Relationship of Gliomas with Tp53 Rs1042522 C > G And Gliomas in Duhok." Journal Of Duhok University 23, no. 2 (2020): 157–65. http://dx.doi.org/10.26682/sjuod.2020.23.2.16.
Pełny tekst źródłaDe Alcântara, Andréia Michelle Alves Cunha, Ivan de Alcântara Barbosa Barros, Ivan Barbosa Barros, et al. "IMPACT OF P21 SER31ARG AND TP53 ARG72PRO POLYMORPHISMS ON HPV SUSCEPTIBILITY AND CERVICAL LESION SEVERITY." ARACÊ 7, no. 7 (2025): 39126–45. https://doi.org/10.56238/arev7n7-226.
Pełny tekst źródłaTsukanov, V. V., A. V. Vasyutin, M. V. Smolnikova, S. Kh Hirlig-ool, E. V. Kasparov, and J. L. Tonkikh. "Polymorphism of apoptosis marker genes in the blood of indigenous people with gastric cancer in the Republic of Tyva." Meditsinskiy sovet = Medical Council, no. 8 (June 10, 2024): 170–75. http://dx.doi.org/10.21518/ms2024-198.
Pełny tekst źródłaAra, S., P. S. Y. Lee, M. F. Hansen, and H. Saya. "Codon 72 polymorphism of the TP53 gene." Nucleic Acids Research 18, no. 16 (1990): 4961. http://dx.doi.org/10.1093/nar/18.16.4961.
Pełny tekst źródłaCosta, Kárita Antunes, and Lidia Andreu Guillo. "TP53 codon 72 polymorphism in pigmentary phenotypes." Journal of Biosciences 37, no. 1 (2012): 33–39. http://dx.doi.org/10.1007/s12038-012-9183-9.
Pełny tekst źródłaDong, Huajie, Tong Zhou, Peng Li, et al. "Association of TP53 polymorphisms with the acquisition of EGFR T790M mutations in patients with first- or second-generation EGFR-TIK progression." Journal of Clinical Oncology 40, no. 16_suppl (2022): e20560-e20560. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e20560.
Pełny tekst źródłaDong, Huajie, Tong Zhou, Peng Li, et al. "Association of TP53 polymorphisms with the acquisition of EGFR T790M mutations in patients with first- or second-generation EGFR-TIK progression." Journal of Clinical Oncology 40, no. 16_suppl (2022): e20560-e20560. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e20560.
Pełny tekst źródłaBulgakova, O., A. Kussainova, and R. Bersimbaev. "The cell cycle regulatory gene polymorphisms TP53 (rs1042522) and MDM2 (rs2279744) in lung cancer: a meta-analysis." Vavilov Journal of Genetics and Breeding 24, no. 7 (2020): 77–784. http://dx.doi.org/10.18699/vj20.673.
Pełny tekst źródłaGrossmann, Vera, Valentina Artusi, Susanne Schnittger, et al. "The TP53 Codon72 Polymorphism Is Associated with TP53 Mutations in Chronic Lymphocytic Leukemia." Blood 118, no. 21 (2011): 1783. http://dx.doi.org/10.1182/blood.v118.21.1783.1783.
Pełny tekst źródłaAhmed, Hasib Uddin, Abdul Hafiz, M. M. Towhidul Islam, and Yearul Kabir. "Exploring the relationship between genetic polymorphisms and cancer in the Bangladeshi population." Journal of Bangladesh Academy of Sciences 49, no. 1 (2025): 1–20. https://doi.org/10.3329/jbas.v49i1.81802.
Pełny tekst źródłaMishchuk, Ya M., Ye V. Kharkivska, S. V. Serga, et al. "Association of TP53 Arg72Pro polymorphism (rs1042522) with bladder cancer risk in the Ukrainian population." Faktori eksperimental'noi evolucii organizmiv 23 (September 9, 2018): 214–18. http://dx.doi.org/10.7124/feeo.v23.1017.
Pełny tekst źródłaLung, For-Wey, Hung-Yu Lin, Chun-Hsiung Huang, Wen-Jen Wu, and Li-Ching Chang. "TP53 codon 72 Gene Polymorphism Paradox in Associated with Various Carcinoma Incidences, Invasiveness and Chemotherapy Responses." International Journal of Biomedical Science 4, no. 4 (2008): 248–54. http://dx.doi.org/10.59566/ijbs.2008.4248.
Pełny tekst źródłaHaghnazari, Lida, and Ramin Sabzi. "Relationship between TP53 and interleukin-6 gene variants and the risk of types 1 and 2 diabetes mellitus development in the Kermanshah province." Journal of Medicine and Life 14, no. 1 (2021): 37–44. http://dx.doi.org/10.25122/jml-2019-0150.
Pełny tekst źródłaDolgikh, Oleg V., and Olga A. Kazakova. "Expression of the TR53 oncosuppressor gene modified with benzo[a]pyrene and the SARS-COV-2 vaccine antigen in an in vitro experiment." Hygiene and sanitation 102, no. 10 (2023): 1043–47. http://dx.doi.org/10.47470/0016-9900-2023-102-10-1043-1047.
Pełny tekst źródłaChandel, Neha, Ashish Chauhan, and Kamlesh Guleria. "The p.Pro47Ser Polymorphism of TP53: A Systematic Review." International Journal of Cancer Research 9, no. 1 (2012): 1–8. http://dx.doi.org/10.3923/ijcr.2013.1.8.
Pełny tekst źródłaGovindhasamy, Rekha, Paramesh Govindhasamy, Rajitha Vanga, and Pushpa Burute. "Role of TP53 Gene Polymorphism in Male Infertility." International Journal of Infertility & Fetal Medicine 12, no. 2 (2021): 44–48. http://dx.doi.org/10.5005/jp-journals-10016-1218.
Pełny tekst źródłaZorić, Arijana, Anđela Horvat, Melita Balija, and Neda Slade. "The Arg72Pro Polymorphism of TP53 in Croatian Population." Croatica Chemica Acta 85, no. 2 (2012): 239–43. http://dx.doi.org/10.5562/cca1866.
Pełny tekst źródłaFutreal, P. A., J. C. Barrett, and R. W. Wiseman. "An Alu polymorphism intragenic to the TP53 gene." Nucleic Acids Research 19, no. 24 (1991): 6977. http://dx.doi.org/10.1093/nar/19.24.6977.
Pełny tekst źródłaDenisov, Evgeniy V., Nadejda V. Cherdyntseva, Nicolay V. Litvyakov, et al. "TP53 mutations and Arg72Pro polymorphism in breast cancers." Cancer Genetics and Cytogenetics 192, no. 2 (2009): 93–95. http://dx.doi.org/10.1016/j.cancergencyto.2009.03.014.
Pełny tekst źródłaGraziani, D., S. Romagnoli, B. Cassani, R. M. Alfano, M. Roncalli, and G. Coggi. "An Ava I polymorphism in the TP53 gene." Molecular and Cellular Probes 13, no. 5 (1999): 393–95. http://dx.doi.org/10.1006/mcpr.1999.0256.
Pełny tekst źródłaIrtegun-Kandemir, Sevgi, Irmak Icen-Taskin, and Omer Munzuroglu. "TP53 rs1042522 polymorphism and early-onset breast cancer." Journal of Research in Medical Sciences 25, no. 1 (2020): 25. http://dx.doi.org/10.4103/jrms.jrms_506_19.
Pełny tekst źródłaUno, M., S. M. Oba-Shinjo, A. Wakamatsu, et al. "Association of TP53 Mutation, p53 Overexpression, and p53 Codon 72 Polymorphism with Susceptibility to Apoptosis in Adult Patients with Diffuse Astrocytomas." International Journal of Biological Markers 21, no. 1 (2006): 50–57. http://dx.doi.org/10.1177/172460080602100108.
Pełny tekst źródłaVieira, Jussane, Afonso Nazário, and João Pesquero. "Abstract PO3-15-02: TP53 GENE POLYMORPHISM AT CODON 72 AS A RESPONSE PREDICTOR FOR NEOADJUVANT CHEMOTHERAPY." Cancer Research 84, no. 9_Supplement (2024): PO3–15–02—PO3–15–02. http://dx.doi.org/10.1158/1538-7445.sabcs23-po3-15-02.
Pełny tekst źródłaIsakova, Jainagul T., E. T. Talaibekova, K. B. Makieva, D. A. Asambaeva, B. B. Sultangazieva, and A. A. Aldashev. "Association between XRCC1 ARG399GLN, TP53 ARG72PRO and MDM2 T309G polymorphisms and the risk of breast cancer in women of the Kyrgyz population." Russian Journal of Oncology 21, no. 3 (2016): 131–35. http://dx.doi.org/10.18821/1028-9984-2016-21-3-131-135.
Pełny tekst źródła